185 related articles for article (PubMed ID: 30626916)
1. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.
Shanmugam V; Griffin GK; Jacobsen ED; Fletcher CDM; Sholl LM; Hornick JL
Mod Pathol; 2019 Jun; 32(6):830-843. PubMed ID: 30626916
[TBL] [Abstract][Full Text] [Related]
2. PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
Hédan B; Rault M; Abadie J; Ulvé R; Botherel N; Devauchelle P; Copie-Bergman C; Cadieu E; Parrens M; Alten J; Zalcman EL; Cario G; Damaj G; Mokhtari K; Le Loarer F; Coulomb-Lhermine A; Derrien T; Hitte C; Bachelot L; Breen M; Gilot D; Blay JY; Donadieu J; André C
Int J Cancer; 2020 Sep; 147(6):1657-1665. PubMed ID: 32212266
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C; Nicolae A; Lack J; Chung HJ; Skarshaug S; Pham TA; Navarro W; Abdullaev Z; Aguilera NS; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
Haematologica; 2020 Apr; 105(4):951-960. PubMed ID: 31439678
[TBL] [Abstract][Full Text] [Related]
4. The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.
Egan C; Lack J; Skarshaug S; Pham TA; Abdullaev Z; Xi L; Pack S; Pittaluga S; Jaffe ES; Raffeld M
Mod Pathol; 2021 Feb; 34(2):336-347. PubMed ID: 32929178
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.
Kemps PG; Hebeda KM; Pals ST; Verdijk RM; Lam KH; Bruggink AH; de Lil HS; Ruiterkamp B; de Heer K; van Laar JA; Valk PJ; Mutsaers P; Levin MD; Hogendoorn PC; van Halteren AG
J Pathol Clin Res; 2021 Jan; 7(1):10-26. PubMed ID: 32852896
[TBL] [Abstract][Full Text] [Related]
6. Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.
Hu B; Patel JL; Tao R; Cannon RB; Monroe M; Goyal G
J Natl Compr Canc Netw; 2022 Mar; 20(6):618-621. PubMed ID: 35325867
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations in histiocytic sarcoma identified by next generation sequencing.
Liu Q; Tomaszewicz K; Hutchinson L; Hornick JL; Woda B; Yu H
Virchows Arch; 2016 Aug; 469(2):233-41. PubMed ID: 27259537
[TBL] [Abstract][Full Text] [Related]
8. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
[TBL] [Abstract][Full Text] [Related]
9. Activating Mutations in
Takada M; Smyth LA; Thaiwong T; Richter M; Corner SM; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31277422
[TBL] [Abstract][Full Text] [Related]
10. Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma.
Kumar J; Al-Kawaaz M; Martin BA; Hegazi MM; Tan B; Gratzinger D
Am J Clin Pathol; 2022 Oct; 158(4):449-455. PubMed ID: 35964234
[TBL] [Abstract][Full Text] [Related]
11. Histiocytic Sarcoma.
Hung YP; Qian X
Arch Pathol Lab Med; 2020 May; 144(5):650-654. PubMed ID: 31070934
[TBL] [Abstract][Full Text] [Related]
12. High frequency of clonal IG and T-cell receptor gene rearrangements in histiocytic and dendritic cell neoplasms.
Huang W; Qiu T; Zeng L; Zheng B; Ying J; Feng X
Oncotarget; 2016 Nov; 7(48):78355-78362. PubMed ID: 27823979
[TBL] [Abstract][Full Text] [Related]
13. A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
[TBL] [Abstract][Full Text] [Related]
14. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
[TBL] [Abstract][Full Text] [Related]
16. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL; Durham BH; Ulaner GA; Drill E; Buthorn J; Ki M; Bitner L; Cho H; Young RJ; Francis JH; Rampal R; Lacouture M; Brody LA; Ozkaya N; Dogan A; Rosen N; Iasonos A; Abdel-Wahab O; Hyman DM
Nature; 2019 Mar; 567(7749):521-524. PubMed ID: 30867592
[TBL] [Abstract][Full Text] [Related]
18. RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors.
Mata DA; Yang SR; Ferguson DC; Liu Y; Sharma R; Benhamida JK; Al-Ahmadie HA; Chakravarty D; Solit DB; Tickoo SK; Gupta S; Arcila ME; Ladanyi M; Feldman DR; Reuter VE; Vanderbilt CM
Urology; 2020 Oct; 144():111-116. PubMed ID: 32721511
[TBL] [Abstract][Full Text] [Related]
19. Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Kordes M; Röring M; Heining C; Braun S; Hutter B; Richter D; Geörg C; Scholl C; Gröschel S; Roth W; Rosenwald A; Geissinger E; von Kalle C; Jäger D; Brors B; Weichert W; Grüllich C; Glimm H; Brummer T; Fröhling S
Leukemia; 2016 Apr; 30(4):937-46. PubMed ID: 26582644
[TBL] [Abstract][Full Text] [Related]
20. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
Serrano C; Romagosa C; Hernández-Losa J; Simonetti S; Valverde C; Moliné T; Somoza R; Pérez M; Vélez R; Vergés R; Domínguez R; Carles J; Ramón Y Cajal S
Cancer; 2016 Jan; 122(1):99-107. PubMed ID: 26479291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
